Senior Laboratory Director, Oncology

The posting, as BillionToOne wrote it

A Rare Opportunity to Shape the Future of Genomics

Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.

Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.

If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong.

BillionToOne is seeking a Senior Laboratory Director, Oncology to lead and own the daily operations of our high-complexity oncology clinical laboratory. Reporting to the SVP of Laboratory Operations, this person owns oncology laboratory operations end to end, with accountability for quality, turnaround time, capacity, cost, and regulatory compliance. This is a full-time, onsite role (2 to 3 days/week) in Menlo Park, CA.

Responsibilities

• Lead, build, and scale the oncology laboratory organization (technologists, supervisors, and operations managers), including headcount planning, hiring, and competency management.
• Own the oncology laboratory operating budget and P&L, including COGS, operating expenses, and capital equipment planning.
• Drive operational performance against turnaround-time (TAT), throughput, capacity, and quality targets; implement process improvements and automation to scale.
• Lead laboratory scale-up, new-assay and instrument onboarding, inspection readiness, and vendor and capital procurement.
• Provide technical oversight of somatic variant interpretation and oncology report sign-out from Northstar liquid biopsy assays, ensuring accuracy and timeliness.
• Troubleshoot technical issues across oncology workflows (liquid biopsy sample prep, NGS library preparation, sequencing, and data analysis).
• Ensure compliance with CLIA, CAP, and NYSDOH standards; oversee Non-Conforming Events, CAPAs, and documentation of SOPs, validations, QC records, competencies, proficiency testing, and report archives.
• Collaborate with bioinformatics, R&D, and medical affairs on assay development and interpretation guidelines; serve as a subject-matter expert on oncology variant interpretation (AMP/CAP/NYS guidelines).

Qualifications

• Doctoral degree (PhD, MD, or equivalent) in genetics, molecular biology, or a related field, with board certification (ABMGG, ABP in Molecular Genetic Pathology, or equivalent).
• Valid or eligible

[…]
l status, veteran status, or disability status.
For more information about how we protect your information, we encourage you to review our Privacy Policy .

BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide.

Our Impact

Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample.
Unity Confirm™ enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne’s Fetal Cell Capture™ Technology.
Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care.

Our Growth

From $0 to $400M+ annualized revenue run-rate in just 6 years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest.

Our Recognition

Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified , with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees.

Our Future

Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started.

Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com